Skip to main content

Table 3 Factors associated with progression-free survival

From: Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer

Characteristics N Univariate analysis Multivariate analysis
HR 95% CI P Adjusted HR 95% CI P
Age, years
 <50 39 1 (Ref) 1 (Ref)
 ≥50 89 1.540 0.958−2.477 0.075 1.377 0.850−2.232 0.194
FIGO stage
 III 77 1 (Ref) 1 (Ref)
 IV 51 1.903 1.244−2.912 0.003 1.358 0.867−2.126 0.182
Primary treatment strategy
 PDS 79 1 (Ref) 1 (Ref)
 NAC 49 2.098 1.373−3.206 0.001 2.103 1.321−3.348 0.002
Residual tumor after PDS/IDS
 Optimal debulking 109 1 (Ref) 1 (Ref)
 Suboptimal debulking 19 1.515 0.867−2.648 0.145 1.587 0.879−2.865 0.126
BRCA status
 Wild-type 77 1 (Ref) 1 (Ref)
 Mutation 51 0.484 0.310−0.755 0.001 0.502 0.318−0.795 0.003
  1. Abbreviations: CA-125 cancer antigen 125, FIGO International Federation of Gynecology and Obstetrics, PDS primary debulking surgery, NAC neoadjuvant chemotherapy, IDS interval debulking surgery, HR hazard ratio, CI confidence interval, Ref reference